Clinical experience with the artificial bone graft substitute Calcibon used following curettage of benign and low-grade malignant bone tumors

Artificial bone graft substitutes, such as Calcibon, are becoming increasingly interesting as they do not cause donor site morbidity which is an advantage compared to autologous bone grafts. The aim of this study was to evaluate the efficacy and potential complications associated with the use of Cal...

Full description

Saved in:
Bibliographic Details
Published in:Scientific reports 2017-05, Vol.7 (1), p.1736-5, Article 1736
Main Authors: Friesenbichler, Joerg, Maurer-Ertl, Werner, Bergovec, Marko, Holzer, Lukas A., Ogris, Kathrin, Leitner, Lukas, Leithner, Andreas
Format: Article
Language:English
Subjects:
692/1537/805
692/308/409
692/4028/546
Adolescent
Adult
Aged
Allografts
Autografts
Benign
Bone cancer
Bone grafts
Bone Neoplasms - complications
Bone Neoplasms - diagnostic imaging
Bone Neoplasms - pathology
Bone Neoplasms - therapy
Bone resorption
Bone Substitutes - pharmacology
Bone Transplantation
Bone tumors
Classification
Curettage
Curettage - adverse effects
Cysts
Female
Humanities and Social Sciences
Humans
Juveniles
Knee
Lesions
Male
Middle Aged
Morbidity
multidisciplinary
Science
Science (multidisciplinary)
Skin & tissue grafts
Young Adult
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Artificial bone graft substitutes, such as Calcibon, are becoming increasingly interesting as they do not cause donor site morbidity which is an advantage compared to autologous bone grafts. The aim of this study was to evaluate the efficacy and potential complications associated with the use of Calcibon. Twenty-seven patients with benign and low-grade malignant bone tumors were treated with curettage and refilling of the bony cavity. Based on the radiological classification system of Neer, these lesions only comprised Grade I lesions, describing cysts that only require curettage and filling, but no additional treatment. At a mean follow up of six months we observed radiological consolidation without resorption of the bone graft substitute. These observations were also made at a mean follow-up of 13 and 32 months, respectively. According to the classification system of Goslings and Gouma we observed six surgical complications. Summing up, Calcibon seems to be a reliable bone graft substitute with low complication rates. However, delayed resorption should be expected. Calcibon seems to be an alternative to autologous bone grafts or allografts in adequate indications.
ISSN:2045-2322
2045-2322
DOI:10.1038/s41598-017-02048-w